ArticleTranslational lung cancer research2025
Pseudoprogression of pleural effusion in lung cancer treated with immunotherapy: a case report.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pulmonary toxicity of immune checkpoint inhibitors.Breathe (Sheffield, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pseudoprogression (PsP) is an atypical response phenomenon increasingly recognized in patients treated with immune checkpoint inhibitors (ICIs), characterized by transient radiologic worsening before subsequent tumor regression. This response pattern complicates the interpretation of treatment efficacy and poses a challenge in distinguishing true disease progression from a treatment-related immune effect. While PsP is most commonly observed as an initial increase in tumor size or the appearance of new lesions, its presentation as pleural effusion is exceedingly rare and may be misdiagnosed as disease progression or immune-related adverse events (irAEs). Prompt recognition of this phenomenon is essential to avoid premature discontinuation of potentially effective therapy. Case Description: Here, we report a rare case of PsP manifesting as pleural effusion in a 56-year-old woman with lung adenocarcinoma and pleural dissemination who was treated with first-line pembrolizumab. Three weeks after treatment initiation, the patient developed new pleural effusion without accompanying symptoms. Pleural fluid analysis revealed adenocarcinoma cells with a predominance of lymphocytes. Despite the cytological findings, the patient's clinical stability and subsequent imaging demonstrated spontaneous resolution of the effusion and regression of disease with continued ICI therapy. The pleural effusion did not recur, and the patient remained on pembrolizumab for over 1 year until eventual progression. Conclusions: This case highlights that PsP can manifest as new-onset pleural effusion, even in the presence of malignant cells in pleural fluid. Clinicians should be aware of this rare presentation, especially when the patient remains clinically stable. Differentiating PsP from irAEs and true progression remains challenging and emphasizes the need for improved biomarkers to guide decision-making. Continuation of ICIs may be appropriate in selected patients with manageable pleural effusion and controlled tumor burden, as inappropriate discontinuation could forfeit potential therapeutic benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.